|
시장보고서
상품코드
2053963
생물제제 수탁 개발 시장 규모, 점유율 및 성장 분석 : 서비스별, 분자 유형별, 개발 단계별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Biologics Contract Development Market Size, Share, and Growth Analysis, By Service (Cell Line Development, Process Development), By Molecule Type (Monoclonal Antibodies, Vaccines), By Phase, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 생물제제 수탁 개발 시장 규모는 2024년에 145억 2,000만 달러로 평가되며, 2025년 161억 9,000만 달러에서 2033년까지 388억 5,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 11.52%로 성장할 것으로 전망되고 있습니다.
세계의 바이오의약품 위탁개발 시장은 바이오의약품에 대한 수요 증가와 제약-바이오 기업의 아웃소싱 증가를 배경으로 괄목할 만한 성장을 거듭하고 있습니다. 주요 성장 요인으로는 모노클로널 항체 및 세포-유전자 치료제의 채택 확대, 바이오 공정 기술의 발전, 위탁개발생산기관(CDMO)의 역량 확대 등을 꼽을 수 있습니다. 모듈식 생산 시설과 바이러스 벡터 생산 시스템에 대한 투자도 이러한 성장을 더욱 촉진하고 있습니다. 또한 단클론 항체 및 백신 관련 전문 서비스 아웃소싱이 증가하는 추세입니다. 그러나 전문 제조 능력의 부족, 높은 운영 비용, 복잡한 규제 요건 등의 문제로 인해 시장 침투를 방해할 수 있으며, 바이오의약품 위탁 개발 시장은 역동적인 상황을 맞이하고 있습니다.
세계의 바이오의약품 위탁개발 시장은 서비스, 분자 유형, 단계, 최종사용자, 지역별로 세분화되어 있습니다. 서비스별로는 세포주 개발, 공정 개발, 분석 개발, 제제 개발로 분류됩니다. 분자 유형별로는 모노클로널 항체, 백신, 융합단백질, 유전자치료제 벡터로 분류됩니다. 개발 단계별로 시장은 초기 단계(전임상/I상)와 후기 단계(II상/III상)로 나뉜다. 최종사용자별로 시장은 대형 제약사, 바이오테크 스타트업, 학계 스핀오프 기업으로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분류됩니다.
세계의 바이오의약품 위탁개발 시장 성장요인
세계의 바이오로직스 위탁개발 시장의 주요 시장 촉진요인 중 하나는 다양한 만성질환 및 복합질환 치료에 효과적이기 때문에 바이오로직스에 대한 수요가 증가하고 있다는 점입니다. 제약업계가 맞춤형 의료와 혁신적 치료법으로 전환함에 따라 전문적인 위탁 개발 서비스의 필요성이 급증하고 있습니다. 이러한 성장은 바이오의약품 연구개발에 대한 투자 증가와 전문 지식과 인프라를 필요로 하는 엄격한 규제 요건에 의해 더욱 촉진되고 있습니다. 그 결과, 바이오테크놀러지 기업 및 제약기업은 바이오의약품 개발을 계약업체에 아웃소싱하여 시장 확대를 촉진하고 업계내 연계를 강화하는 추세가 강화되고 있습니다.
세계의 바이오의약품 위탁개발 시장 억제요인
세계의 바이오의약품 위탁개발 시장의 주요 시장 억제요인 중 하나는 바이오의약품의 제조 및 시험을 규제하는 복잡하고 엄격한 규제 환경입니다. 안전성, 유효성, 품질 기준 준수에 대한 광범위한 요구사항은 계약개발기관(CDO)에게 큰 도전이 될 수 있습니다. 이러한 복잡성은 운영 비용을 증가시킬 뿐만 아니라, 제품 개발 및 승인까지의 기간을 연장시키는 원인이 되기도 합니다. 또한 규제 변경과 감시 강화는 CDO에 불확실성을 야기하여 투자 의욕을 떨어뜨리고 시장 수요에 빠르게 적응할 수 있는 능력을 제한할 수 있습니다. 그 결과, 바이오의약품 위탁개발 부문 전체의 성장을 저해하는 결과를 초래할 수 있습니다.
세계 바이오의약품 위탁개발 시장 동향
세계의 바이오의약품 위탁개발 시장에서는 세포치료제, 유전자치료제, 이중특이성 항체 등 복잡한 바이오의약품에 대한 수요를 배경으로 특정 양식에 특화된 아웃소싱으로 큰 변화를 보이고 있습니다. CDO(Contract Development Organization)는 과학적 전문 지식과 혁신적인 제제 기술을 활용하여 이러한 분야의 역량을 강화하고 있습니다. 스폰서들이 고유한 전문성과 다학제적 접근 방식을 중시하는 가운데, 새로운 제품 개발을 위한 확장 가능한 솔루션과 최첨단 플랫폼을 제공할 수 있는 CDO가 경쟁 우위를 점하고 있습니다. 이러한 추세는 끊임없이 진화하는 바이오 제약 산업에서 전략적 파트너십과 첨단 역량이 중요하다는 것을 강조하고 있으며, 전문성을 갖춘 기업이 시장 리더로 자리매김하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 생물제제 수탁 개발 시장 규모 : 서비스별
세계의 생물제제 수탁 개발 시장 규모 : 분자 유형별
세계의 생물제제 수탁 개발 시장 규모 : 단계별
세계의 생물제제 수탁 개발 시장 규모 : 최종사용자별
세계의 생물제제 수탁 개발 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Biologics Contract Development Market size was valued at USD 14.52 Billion in 2024 and is poised to grow from USD 16.19 Billion in 2025 to USD 38.85 Billion by 2033, growing at a CAGR of 11.52% during the forecast period (2026-2033).
The global market for biologics contract development is experiencing significant growth fueled by an escalating demand for biologic therapeutics and increased outsourcing by pharmaceutical and biotechnology firms. Key drivers include the rising adoption of monoclonal antibodies and cell and gene therapies, advancements in bioprocessing technologies, and the expansion of contract development and manufacturing organization (CDMO) capabilities. Investment in modular production facilities and viral vector production systems further supports this growth. Additionally, the trend towards outsourcing specialized services in monoclonal antibodies and vaccines is on the rise. However, challenges such as limited specialized manufacturing capacity, high operational costs, and complex regulatory requirements may hinder market penetration, creating a dynamic landscape for biologics contract development.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biologics Contract Development market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biologics Contract Development Market Segments Analysis
Global biologics contract development market is segmented by service, molecule type, phase, end-user,and region. Based on service, the market is segmented into cell line development, process development, analyticaldevelopment,and formulation development. Based on molecule type, the market is segmented into monoclonal antibodies, vaccines, fusion proteins,and gene therapy vectors. Based on phase, the market is segmented into Early Stage (Preclinical/Phase I) and Late Stage (Phase II/III). Based on end-user, the market is segmented into large pharma, biotech startups,and academic spin-offs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America,and Middle East & Africa.
Driver of the Global Biologics Contract Development Market
One of the key market drivers for the Global Biologics Contract Development Market is the increasing demand for biologics due to their effectiveness in treating various chronic and complex diseases. As the pharmaceutical industry shifts toward personalized medicine and innovative therapies, the need for specialized contract development services has surged. This growth is further propelled by the rising investment in research and development of biopharmaceuticals, along with stringent regulatory requirements that necessitate expert knowledge and infrastructure. Consequently, biotech and pharmaceutical companies are increasingly outsourcing biologics development to contract providers, enhancing market expansion and fostering collaboration within the industry.
Restraints in the Global Biologics Contract Development Market
One key market restraint for the global biologics contract development market is the complex and stringent regulatory environment governing biologics manufacturing and testing. The extensive requirements for compliance with safety, efficacy, and quality standards can pose significant challenges for contract development organizations (CDOs). This complexity not only increases operational costs but also leads to prolonged timelines for product development and approval. Furthermore, any regulatory changes or increased scrutiny can create uncertainties for CDOs, potentially discouraging investment and limiting their ability to adapt swiftly to market demands, thereby hindering the overall growth of the biologics contract development sector.
Market Trends of the Global Biologics Contract Development Market
The Global Biologics Contract Development market is witnessing a significant shift towards specialized modality outsourcing, driven by the demand for complex biologics such as cell therapies, gene therapies, and bispecific antibodies. Contract development organizations (CDOs) are enhancing their capabilities in these areas, leveraging scientific expertise and innovative formulation techniques. As sponsors prioritize distinct domain knowledge and interdisciplinary approaches, CDOs that can offer scalable solutions and cutting-edge platforms for novel product development are gaining a competitive edge. This trend emphasizes the importance of strategic partnerships and advanced capabilities in the ever-evolving biologics landscape, positioning those with specialization as leaders in the market.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Biologics Contract Development Market Size by Service & CAGR (2026-2033)
- Market Overview
- Cell Line Development
- Process Development
- Analytical Development
- Formulation Development
Global Biologics Contract Development Market Size by Molecule Type & CAGR (2026-2033)
- Market Overview
- Monoclonal Antibodies
- Vaccines
- Fusion Proteins
- Gene Therapy Vectors
Global Biologics Contract Development Market Size by Phase & CAGR (2026-2033)
- Market Overview
- Early Stage (Preclinical/Phase I)
- Late Stage (Phase II/III)
Global Biologics Contract Development Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Large Pharma
- Biotech Startups
- Academic Spin-offs
Global Biologics Contract Development Market Size & CAGR (2026-2033)
- North America (Service, Molecule Type, Phase, End-User)
- US
- Canada
- Europe (Service, Molecule Type, Phase, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Service, Molecule Type, Phase, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Service, Molecule Type, Phase, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Service, Molecule Type, Phase, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Lonza Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalent Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujifilm Diosynth Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Rentschler Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cytiva (Danaher)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cobra Biologics (Charles River)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim BioXcellence
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- KBI BioPharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbCellera Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ATUM Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Horizon Discovery (PerkinElmer)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Just Biotherapeutics (Juno)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MassBio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abzena Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biologics by Design
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
